Advanced therapy is delayed in pediatric South Asian inflammatory bowel disease patients in the United States
Year: 2025
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: South Asian pediatric inflammatory bowel disease (SA pIBD) is a novel at-risk demographic group for pediatric IBD. However, the disease characteristics and treatment strategies for SA pIBD in the United States remain poorly described. METHODS: In this retrospective cohort study of 147 patients, SA patients with pIBD (n = 55) were matched (~1:2) to non-South Asian (NSA, n = 92) patients with pIBD by age, sex, and disease subtype. Study outcomes included demographics, disease extent and severity, treatments utilized, and patient perspectives on pIBD and its treatment. RESULTS: Among 55 SA and matched 92 NSA pIBD patients, mean age of presentation was 12 years old, with male predominance (65%), and majority with a Crohn's diagnosis (65%). Very early-onset IBD (VEOIBD) was reported in 5.5% of SA pIBD. SA pIBD patients more frequently presented with weight loss, left-sided disease, upper gastrointestinal manifestations, and elevated erythrocyte sedimentation rate. SA pIBD patients were less likely to use biologic therapies as their initial treatment (9.1% vs. 30.4%, p < 0.005), with a lower cumulative rate of biologic use. Instead, SA pIBD were more likely to use mesalamine or other treatments as their initial therapy. CONCLUSIONS: SA pIBD had unique phenotypic characteristics compared to NSA pIBD. SA pIBD patients were less likely to initiate biologic therapies as their initial treatment and had a longer time-to-initiation of biologic therapies.
DOI: 10.1002/jpn3.70233
Authors: Megha Tandon, Jennifer Bachand, Nurgul Yegembayeva, Lauren V. Collen, Sushrut Jangi
Institutions: Tufts University, Boston Children's Hospital, Tufts Medical Center
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4415268607